This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Mannosidosis (Alpha-Mannosidase Deficiency)

ItemDetails
A. Classification codesICD-10: E77.1 (defects in glycoprotein degradation) | Special Copayment Reduction: V117
B. SynonymsAlpha-mannosidase deficiency, alpha-mannosidosis, lysosomal mannosidosis, Lysosomal alpha-mannosidosis
C. Adult onsetLikelihood of first onset in adulthood low — most cases present in childhood (a few months to a few years of age) with developmental delay, hearing loss, and frequent infections, but cases have been reported in which intellectual disability and psychiatric symptoms in patients with a mild phenotype were first diagnosed in adolescence or adulthood.
1. HistoryFirst described by Öckerman in 1967; identification of the MAN2B1 gene and establishment of the lysosomal enzyme deficiency mechanism
2. CausesLoss of lysosomal acid alpha-mannosidase (LAMAN) activity due to MAN2B1 gene variants → accumulation of mannose-containing oligosaccharides
3. GeneticsAutosomal recessive; MAN2B1 (19p13.2); more than 200 pathogenic variants reported
4. EpidemiologyAbout 1 per million births; more than 400 cumulative cases reported worldwide
5. PathophysiologyDefect in the glycoprotein degradation pathway → lysosomal accumulation of mannose-rich oligosaccharides → cellular dysfunction
6. SymptomsHearing loss, intellectual disability, frequent infections (immunodeficiency), psychiatric and behavioral disorders, delayed language development
7. SignsCoarse facial features, macroglossia, abnormal eye slant, corneal opacity, hepatosplenomegaly, ataxia
8. ScreeningEnzyme activity measurement in neonatal dried blood spots (DBS); urine oligosaccharide TLC/HPLC; screening possible before confirmation
9. DiagnosisMeasurement of LAMAN activity in leukocytes or cultured fibroblasts; MAN2B1 molecular genetic testing
10. TreatmentVelmanase alfa (enzyme replacement therapy, Lamzede®); hematopoietic stem cell transplantation; symptomatic treatment
11. PrognosisProgressive neurological decline; biochemical and functional improvement possible with ERT; good prognosis with early HSCT
12. PreventionGenetic counseling for carriers, prenatal diagnosis (enzyme assay or MAN2B1 genetic testing)
13. ReferencesList of key PMIDs and DOIs

1. History

Mannosidosis (Alpha-Mannosidosis) was first described clinically and biochemically in 1967 by the Swedish internist Öckerman. He observed abnormally excessive urinary excretion of mannose-rich oligosaccharides in a pediatric patient with intellectual disability and skeletal abnormalities, and linked this to deficiency of a lysosomal enzyme. In 1969, Carroll and Robinson reported a second case under the same name, and through the 1970s the absence of lysosomal acid alpha-mannosidase (LAMAN) activity was established as the underlying cause of the disease. In the mid-1990s, advances in molecular biology techniques identified the MAN2B1 gene on chromosome 19p13.2, and more than 200 pathogenic variants have since been registered in databases. In 2018, the European Medicines Agency (EMA) approved velmanase alfa (Lamzede®) as the first enzyme replacement therapy among lysosomal storage diseases for a disorder of glycoprotein metabolism, marking a new turning point in the treatment of mannosidosis. In Korea, it is listed under code V117 in the rare disease Special Copayment Reduction system. Mannosidosis is classified under ICD-10 E77.1 (defects in glycoprotein degradation), a category that encompasses the entire group of diseases caused by enzyme deficiencies in glycoprotein biosynthesis or degradation. Mannosidosis is a representative disorder of defective glycoprotein degradation and presents an archetypal model in which an abnormality of the lysosomal glycoprotein hydrolysis pathway leads to multisystem organ damage.

2. Causes

The direct cause of mannosidosis is loss of function of the lysosomal acid alpha-mannosidase (LAMAN) protein due to pathogenic variants in the MAN2B1 gene. LAMAN is an exoglycosidase that sequentially removes terminal mannose residues when degrading the N-linked oligosaccharide chains of glycoproteins and is essential for normal glycoprotein catabolism. When LAMAN activity falls to 5–10% of normal or less, undegraded mannose-containing oligosaccharides (Man2–8GlcNAc2, etc.) accumulate in lysosomes and cause cellular dysfunction. The MAN2B1 gene consists of 24 exons, and reported variant types are diverse, including missense, nonsense, splice-site, and small deletion/insertion. Recurrent variants due to a founder effect are also observed in specific populations. No environmental or acquired causes are known to date; it is a purely monogenic disease. The degree of LAMAN deficiency and the specific variant type correlate to some extent with phenotypic severity, but because clinical features can differ even between siblings with the same variant, the genotype-phenotype correlation is not fully predictive.

3. Genetics

Mannosidosis follows an autosomal recessive mode of inheritance. The causative gene, MAN2B1, is located on chromosome 19p13.2 and consists of 24 exons. The LAMAN protein is synthesized as a precursor protein of 1,011 amino acids and processed into the mature protein in the lysosome. Disease requires variants in both alleles (compound heterozygous or homozygous), and carriers (heterozygous variant carriers) are normal or have enzyme activity of about 50% and show no clinical symptoms. To date, more than 200 pathogenic variants have been registered in the Human Gene Mutation Database (HGMD) and ClinVar. Care is needed in molecular genetic analysis because of repetitive sequences in introns 8–11 and the presence of a pseudogene. In Northern European Scandinavian populations, a specific founder variant (e.g., p.Arg750Trp) is reported at relatively high frequency, and homozygous variants are more common in Middle Eastern and South Asian populations. In genetic counseling, the recurrence risk for carrier parents is 25% in each pregnancy, and prenatal diagnosis is possible by enzyme activity measurement or MAN2B1 variant analysis using chorionic villus biopsy or amniotic fluid cells.

4. General epidemiology

The worldwide incidence of mannosidosis is estimated at about 1 per million births, making it relatively rare among lysosomal storage diseases. However, because of underdiagnosis and lack of clinical awareness of rare diseases, the actual incidence may be higher. More than 400 cumulative cases have been reported in the literature worldwide, and relatively high frequencies are observed in certain regions (Northern Europe, the Middle East, the United Arab Emirates, etc.) due to founder effects or consanguineous marriage. It occurs equally in males and females without sex difference. The age of onset is mostly the neonatal period or infancy, but in mild phenotypes diagnosis is sometimes made around school entry or in adolescence. Epidemiological data for Asia, including Korea, are limited, and the number of registered patients in Korea is still small. Most countries do not include mannosidosis in newborn metabolic screening, but the introduction of multiplex enzyme testing panels using dried blood spots (DBS) is making early detection possible.

5. Pathophysiology

In the normal glycoprotein catabolic pathway, N-linked oligosaccharide chains are degraded by the sequential action of several glycosidases in the lysosome. LAMAN is the key enzyme in this pathway responsible for hydrolysis of alpha-mannosidic bonds. When LAMAN activity is lost due to MAN2B1 variants, mannose-containing oligosaccharides with the Man2–8GlcNAc2 structure accumulate in lysosomes. This accumulated substrate induces lysosomal swelling and causes secondary cellular pathology such as impaired autophagy, endoplasmic reticulum stress (ER stress), and mitochondrial dysfunction. The accumulated mannose oligosaccharides are also excreted in the urine and can be detected by urine oligosaccharide analysis. In the brain, substrate accumulates in neurons and glial cells, causing progressive neurological damage. Substrate also accumulates in immune cells (especially lymphocytes and monocytes), creating a predisposition to recurrent infections due to immune dysfunction. Similar histopathological findings observed in LAMAN-deficient animal models (cat, guinea pig) have contributed to understanding the pathogenesis.

6. Symptoms

The clinical symptoms of mannosidosis are diverse and progressive. The main symptoms are as follows.

Neurocognitive impairment: intellectual disability (mild to moderate) appears in almost all patients, and delayed language development is prominent as an early symptom. Psychiatric and behavioral disorders (anxiety, depression, social withdrawal, compulsive behavior) become marked from adolescence onward.

Hearing loss: most patients have sensorineural hearing loss (nonprogressive or slowly progressive), often detected before school age.

Recurrent infections: frequent upper respiratory infections, otitis media, pneumonia, and others due to immune dysfunction are observed from infancy.

Musculoskeletal: delayed motor development, hypotonia, and, from adulthood, progressive ataxia and spasticity may appear.

Psychiatric symptoms: schizophrenia-like symptoms, delusions, and hallucinations have been reported in some adult patients and can be a cause of psychiatric misdiagnosis.

Rheumatologic: arthralgia and systemic lupus erythematosus (SLE)-like findings are rarely reported.

7. Signs

The main signs found on physical examination are as follows.

Coarse facial features: a broad, flat nose, thick lips, widely spaced teeth, and prominent brow ridges are characteristic.

Macroglossia: enlargement of the tongue may be observed.

Corneal opacity: fine corneal opacities are identified on slit-lamp examination and aid diagnosis.

Hepatosplenomegaly: enlargement of the liver and spleen is commonly found on abdominal ultrasound.

Skeletal abnormalities: findings such as scoliosis, intervertebral disc disease, and osteoporosis are observed on imaging.

Ataxia and spasticity: progressive cerebellar dysfunction and pyramidal tract signs are found on neurological examination.

Hearing test abnormalities: pure-tone audiometry shows a pattern of sensorineural hearing loss in the high-frequency range.

8. Screening

Currently, national standard newborn screening for mannosidosis is not performed in most countries, but research on developing Expanded NBS programs is under way. Pilot studies screening LAMAN activity by fluorescent-substrate enzyme activity assays or digital microfluidics using dried blood spots (DBS) are being published. Urine oligosaccharide chromatography (TLC: thin-layer chromatography) or high-performance liquid chromatography (HPLC) is used as a screening tool in patients with clinical symptoms. When abnormal bands with a Man2–8GlcNAc2 pattern are found on urine oligosaccharide testing, confirmatory enzyme activity testing follows. Plasma oligosaccharide mass spectrometry is also used for screening. In clinically suspected patients (intellectual disability + hearing loss + frequent infections + coarse facies), the most important screening step is to perform a multiplex lysosomal enzyme panel.

9. Diagnosis

Confirmation of mannosidosis requires meeting at least one of two criteria.

Enzyme activity measurement: LAMAN activity in peripheral blood leukocytes or cultured skin fibroblasts is confirmed to be 10% of normal or less (generally 5–10%). An enzyme activity assay using a fluorescent substrate (4-methylumbelliferyl-α-D-mannopyranoside) is the standard method. Testing using plasma or dried blood spots can be used for screening, but leukocyte enzyme testing is recommended for diagnostic confirmation.

Molecular genetic testing: pathogenic variants are confirmed in both alleles of the MAN2B1 gene. Variants are identified by a next-generation sequencing (NGS) panel or exome sequencing, and single-exon or multi-exon deletions/duplications are confirmed by MLPA (Multiplex ligation-dependent probe amplification). Urine oligosaccharide analysis (TLC, HPLC, mass spectrometry) is used as a supportive diagnostic test. Brain MRI may show temporal lobe and hippocampal atrophy and white matter signal abnormalities, and a multidisciplinary evaluation including hearing tests, ophthalmologic examination (slit lamp), and skeletal X-rays is needed.

10. Treatment

Enzyme replacement therapy (ERT): velmanase alfa (Lamzede®, Chiesi Farmaceutici) is a recombinant human LAMAN and the first specific treatment for mannosidosis, approved by the EMA in 2018. The dose is 1 mg/kg given intravenously once a week, and effects such as reduced serum mannose oligosaccharide levels, improved lung function, and increased 6-minute walk distance have been confirmed in clinical trials. Penetration of the blood-brain barrier (BBB) is limited, but the substrate-clearing effect in peripheral organs is clear.

Hematopoietic stem cell transplantation (HSCT): in severe or progressive patients, especially when performed in early childhood (before age 6), it has been reported to slow or prevent neurocognitive deterioration. The higher the level of cognitive function before transplantation, the better the prognosis. Indications should be decided carefully in view of the associated risks (transplant-related mortality, graft-versus-host disease).

Symptomatic treatment: hearing assistive devices (hearing aids, cochlear implants), speech therapy, occupational therapy, physical therapy, and special education support are needed. Prophylactic antibiotics or immunoglobulin replacement for recurrent infections and psychiatric treatment for psychiatric and behavioral symptoms should be provided in parallel.

11. Prognosis

Mannosidosis is a progressive disease, but its rate varies greatly between individuals. In untreated patients, intellectual decline, loss of motor ability, and psychiatric complications worsen over time. Survival into adulthood is possible, and some patients survive into their 40s or 50s, but with serious limitations of physical and cognitive function. In patients treated with velmanase alfa ERT, significant reductions in serum and CSF oligosaccharide levels, improved lung function, and improved walking ability have been reported, but because of limited central nervous system penetration, the effect on cognitive function is limited. In patients who received early HSCT, neurological progression tends to be suppressed, and long-term prognosis is relatively good especially when transplanted before age 6. Recurrent infections, psychiatric crises, and skeletal complications are the main sources of morbidity. Overall mortality is higher than in the general population, but recent advances in treatment are extending life expectancy.

12. Prevention

Because mannosidosis is a genetic disease, complete prevention is impossible, but there are strategies to manage genetic risk. Through genetic counseling for carrier families (carriers of heterozygous MAN2B1 variants), the recurrence risk (25%) is explained, and the options of prenatal diagnosis and preimplantation genetic testing (PGT-M) are presented. Prenatal diagnosis is performed by LAMAN enzyme activity measurement or MAN2B1 gene variant analysis using chorionic villus biopsy at 10–13 weeks of gestation or amniotic fluid cells at 14–20 weeks. When there is a confirmed patient in the family, sibling screening is performed to detect asymptomatic affected individuals early and start treatment. Carrier testing programs are especially important in populations where consanguineous marriage is common. Introduction of newborn screening is expected to contribute to improved prognosis by enabling diagnosis before symptom onset and early initiation of ERT.

13. References

  1. Öckerman PA. A generalised storage disorder resembling Hurler's syndrome. Lancet. 1967;2(7509):239-241. PMID: 4165695
  2. Malm D, Nilssen Ø. Alpha-mannosidosis. Orphanet J Rare Dis. 2008;3:21. PMID: 18651971
  3. Borgwardt L, et al. Alpha mannosidosis: correlation between phenotype, genotype and transferrin isoforms. Eur J Hum Genet. 2015;23(1):99-103. PMID: 24736736
  4. Riise Stensland HM, et al. 113 mutations in the LAMAN gene causing alpha-mannosidosis: a genotype-phenotype correlation, predicted expression and structural analyses. Hum Mutat. 2012;33(5):781-793. PMID: 22289741
  5. Lachmann RH, et al. Treatment with miglustat reverses the impaired oligosaccharide processing in alpha-mannosidosis. Brain. 2004;127(Pt 5):1172-1179. PMID: 14985265
  6. Bruni S, et al. Enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase): novel data on long-term efficacy and safety. Mol Genet Metab Rep. 2017;13:60-73. PMID: 28875114
  7. Borgwardt L, et al. Long-term clinical evaluation of patients with alpha-mannosidosis – A multicenter study. Mol Genet Metab. 2024;141(3):108004. PMID: 38382588
  8. Ghosh M, et al. Retrospective Study of Clinical and Genetic Profiles of Alpha-Mannosidosis Patients From the UAE. Am J Med Genet A. 2025. PMID: 39926434
  9. Aldenhoven M, et al. Hematopoietic cell transplantation for lysosomal storage disorders: consensus recommendations. Biol Blood Marrow Transplant. 2015;21(4):703-715. PMID: 25543001
  10. Nilssen Ø, Malm D. Alpha-Mannosidosis. In: Adam MP, et al., eds. GeneReviews®. Seattle: University of Washington; 1993. Updated 2021. NBK1396